Page 2 - Biocon Ltd News

Biocon to integrate Biocon Biologics in $5.5-bn tranx, pivots away from IPO

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Biocon board to weigh BBL stake buyout, fundraising options on December 6

Biocon's board will meet on December 6 to consider acquiring Biocon Biologics shares from minority investors through cash or a share swap, and to approve fundraising options such as QIP, rights issue

Biocon stock tanks 6% on heavy volumes; what's triggered the sell-off?

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for investment in Biocon Biologics, an unlisted material subsidiary of the company.

Debt restructuring to reduce interest costs by ₹300 cr by FY27: Biocon CEO

CEO Shreehas Tambe says debt reduction, US state tie-ups, and five fresh product launches will strengthen Biocon Biologics' global biosimilar play

Stocks to Watch today: Bajaj Finserv, Biocon, BSE, Groww, TMCV, Tata Power

Stocks to Watch today: Groww, Tata Motors CV, Bajaj Finserv, Biocon, Bharat Forge, BSE and Tata Power are among the stocks to watch today, November 12, 2025

Biocon Q2FY26 results: Consolidated net profit at ₹84.5 cr, revenue up 21%

The biosimilars segment, operated by Biocon Biologics, reported revenues of Rs 2,721 crore, reflecting strong 25 per cent year-on-year growth

Q2 FY26 results today: Bajaj Finserv, Biocon, Godrej, and more on Nov 11

Q2FY26 company results: Firms including Bajaj Holdings & Investment, Bharat Forge, Bosch, Cera Sanitaryware and Hindustan Copper are also to release their July-September earnings reports today

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has received an approval from Health Canada for chronic autoimmune conditions treatment medications Yesintek and Yesintek IV. The notice of compliance (NOC) granted by Health Canada is for Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion), Biocon Ltd said in a regulatory filing. Yesintek and Yesintek IV are biosimilars to Stelara (ustekinumab injection) and Stelara IV (ustekinumab for injection, solution for intravenous infusion), respectively. The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October, the company said. "Health Canada's approval of Yesintek marks a significant milestone in our mission to expand global access to high-quality biosimilars," Biocon Biologics CEO & Managing Director Shreehas Tambe said. He further said, "Building on our successful US launch, this approval strengthens our presence in ...

Here's why Biocon shares were trading higher on the bourses on October 20

Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon, announced the expansion of its strategic collaboration with Civica, Inc. (Civica)

Biocon Biologics expands Civica tie-up to launch pvt-label insulin in US

The move aims to increase the availability of affordable insulin for the country's 38.4 million diabetes patient

Stocks to watch, Oct 17: RIL, Infosys, Jio Fin, Wipro, Havells, Canara HSBC

Around 7:20 AM, GIFT Nifty futures were down 41.6 points at 25,614.5, indicating a negative start.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin

The USFDA's tentative approval means Biocon Pharma's Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drug